68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

Alessio Imperiale; Vincent Poindron; Matias Martinez; Patrick Ohlmann; Thomas H. Schindler; Soraya El Ghannudi

doi:10.1097/RLU.0000000000003185

⁶⁸Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

Alessio Imperiale
, Vincent Poindron
, Matias Martinez
, Patrick Ohlmann
, Thomas H. Schindler
, Soraya El Ghannudi

Division of Nuclear Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and 18F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to 18F-FDG uptake, which reflects nonspecific leukocyte infiltration, 68Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of 68Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive 18F-FDG PET/CT results.

Original language	English
Pages (from-to)	E416-E418
Journal	Clinical nuclear medicine
Volume	45
Issue number	9
DOIs	https://doi.org/10.1097/RLU.0000000000003185
State	Published - Sep 1 2020

Keywords

DOTATOC
FDG
PET
cardiac magnetic resonance
cardiac sarcoidosis

Access to Document

10.1097/RLU.0000000000003185

Cite this

@article{3bdb6fa3487c498b85c86c516e9c23f8,

title = "68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis",

abstract = "Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and 18F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to 18F-FDG uptake, which reflects nonspecific leukocyte infiltration, 68Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of 68Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive 18F-FDG PET/CT results.",

keywords = "DOTATOC, FDG, PET, cardiac magnetic resonance, cardiac sarcoidosis",

author = "Alessio Imperiale and Vincent Poindron and Matias Martinez and Patrick Ohlmann and Schindler, \{Thomas H.\} and \{El Ghannudi\}, Soraya",

year = "2020",

month = sep,

day = "1",

doi = "10.1097/RLU.0000000000003185",

language = "English",

volume = "45",

pages = "E416--E418",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

number = "9",

}

TY - JOUR

T1 - 68Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

AU - Imperiale, Alessio

AU - Poindron, Vincent

AU - Martinez, Matias

AU - Ohlmann, Patrick

AU - Schindler, Thomas H.

AU - El Ghannudi, Soraya

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and 18F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to 18F-FDG uptake, which reflects nonspecific leukocyte infiltration, 68Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of 68Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive 18F-FDG PET/CT results.

AB - Cardiac sarcoidosis (CS) has a poor prognosis related to life-threating arrhythmias and heart failure. Treatment includes anti-inflammatory therapies and implantable pacemaker and/or cardioverter defibrillator. The presence of cardiac devices and physiologic myocardial glucose uptake are major limitations of both cardiac magnetic resonance and 18F-FDG PET/CT, reducing their diagnostic value. Somatostatin-based PET/CT has been proposed to detect active CS. Contrarily to 18F-FDG uptake, which reflects nonspecific leukocyte infiltration, 68Ga-DOTATOC may identify active granulomatosis. Herein, we underline the specificity of 68Ga-DOTATOC PET in challeging clinical situations including refractory CS, and chronic CS in patients with cardiac device, or false-positive 18F-FDG PET/CT results.

KW - DOTATOC

KW - FDG

KW - PET

KW - cardiac magnetic resonance

KW - cardiac sarcoidosis

UR - https://www.scopus.com/pages/publications/85089301758

U2 - 10.1097/RLU.0000000000003185

DO - 10.1097/RLU.0000000000003185

M3 - Article

C2 - 32604122

AN - SCOPUS:85089301758

SN - 0363-9762

VL - 45

SP - E416-E418

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 9

ER -

⁶⁸Ga-DOTATOC PET for Treatment Efficacy Evaluation of Cardiac Sarcoidosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this